文献速递耳科与耳神经

鼓室内治疗在梅尼埃病中的疗效与早期眩晕控制评估

Intratympanic Therapies in Ménière Disease: Evaluation of Outcomes and Early Vertigo Control.
PubMed 文献 · Laryngoscope · 2018-10-03

该回顾性研究纳入2005至2017年单侧确诊梅尼埃病的成人患者,比较鼓室内地塞米松与庆大霉素的疗效。地塞米松组失败率38%,庆大霉素组10%(P=0.025);庆大霉素组注射次数更少且失败时间更长,两组听力变化无差异。结论认为鼓室内庆大霉素作为初始治疗安全有效。

要点

  • 鼓室内庆大霉素失败率10%,低于地塞米松的38%(P=0.025)。
  • 庆大霉素组平均注射2.7次,少于地塞米松组的3.3次(P=0.011)。
  • 两组纯音测听较基线变化无差异(P=0.30)。

核心结论

  • 鼓室内庆大霉素作为梅尼埃病初始治疗安全有效,可早期及长期控制眩晕。

研究设计与样本

  • 回顾性研究,纳入2005至2017年单侧确诊梅尼埃病成人患者,随访至少6个月。

主要发现

  • 地塞米松组平均注射3.3次,庆大霉素组2.7次(P=0.011)。
  • 地塞米松组失败12例(38%),庆大霉素组失败7例(10%)(P=0.025)。
  • 地塞米松组平均失败时间5个月,庆大霉素组27个月。
  • 两组纯音测听较基线变化无差异(P=0.30)。

关键数值与推荐

  • 失败定义为需要更激进的治疗。
  • 庆大霉素每2周注射一次,最多3次,直至眩晕控制。
  • 地塞米松每周注射一次,最多3次;症状复发可重复治疗。

临床怎么用

  • 可考虑鼓室内庆大霉素作为梅尼埃病初始治疗以早期控制眩晕。
  • 地塞米松失败后可改用庆大霉素。

局限性

  • 回顾性研究设计,证据等级为3。
  • 2011年前后治疗方案调整,非随机分组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate outcomes of intratympanic (IT) dexamethasone and gentamicin in Ménière Disease (MD). METHODS: Charts of adult patients with unilateral definite MD receiving IT gentamicin or dexamethasone from 2005 to 2017 were retrospectively reviewed. All patients had at least 6 months follow-up. Failure in each group was defined as the need for more aggressive therapy. Prior to 2011, all patient received IT gentamicin, administered as primary therapy after failure of conservative treatment measures. Gentamicin was administered every 2 weeks, up to three injections, until vertigo control was achieved. Beginning in 2011, the treatment protocol shifted to IT dexamethasone as initial treatment, with gentamicin used for dexamethasone failures. Dexamethasone was administered weekly for up to three injections. Treatments could be repeated if symptoms recurred. RESULTS: Thirty-three patients received IT dexamethasone, and 70 patients received IT gentamicin. Dexamethasone patients received a mean of 3.3 injections compared to 2.7 in the gentamicin group (P = 0.011). There were 12 (38%) failures in the dexamethasone group and only seven (10%) gentamicin failures (P = 0.025). No patients failed both treatments. The mean time to failure in the dexamethasone group was 5 months, whereas in the gentamicin group it was 27 months. Change in pure tone audiometry from baseline was not different between treatment groups (P = 0.30). CONCLUSION: Subjects receiving IT gentamicin required fewer injections and had a significantly longer time to failure than IT dexamethasone. Audiometric outcomes were similar between the groups. The use of IT gentamicin as initial therapy for early and long-term control of MD is safe and effective. LEVEL OF EVIDENCE: 3 Laryngoscope, 129:216-221, 2019.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Naples JG, Henry L, Brant JA, et al. Intratympanic Therapies in Ménière Disease: Evaluation of Outcomes and Early Vertigo Control. Laryngoscope. 2018. PMID: 30284276. doi:10.1002/lary.27392

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。